Literature DB >> 26488908

PEGylated Cu3BiS3 hollow nanospheres as a new photothermal agent for 980 nm-laser-driven photothermochemotherapy and a contrast agent for X-ray computed tomography imaging.

Shu-Mei Zhou1, De-Kun Ma1, Sheng-Hui Zhang2, Wei Wang2, Wei Chen1, Shao-Ming Huang1, Kang Yu2.   

Abstract

Developing multifunctional near-infrared (NIR) light-driven photothermal agents is in high demand for efficient cancer therapy. Herein, PEGylated Cu3BiS3 hollow nanospheres (HNSs) with an average diameter of 80 nm were synthesized through a facile ethylene glycol-mediated solvothermal route. The obtained PEGylated Cu3BiS3 HNSs exhibited strong NIR optical absorption with a large molar extinction coefficient of 4.1 × 10(9) cm(-1) M(-1) at 980 nm. Under the irradiation of a 980 nm laser with a safe power density of 0.72 W cm(-2), Cu3BiS3 HNSs produced significant photothermal heating with a photothermal transduction efficiency of 27.5%. The Cu3BiS3 HNSs also showed a good antitumoral drug doxorubicin (DOX) loading capacity and pH- and NIR-responsive DOX release behaviors. At a low dosage of 10 μg mL(-1), HeLa cells could be efficiently killed through a synergistic effect of chemo- and photothermo-therapy respectively based on the DOX release and the photothermal effect of Cu3BiS3 HNSs. In addition, Cu3BiS3 HNSs displayed a good X-ray computed tomography (CT) imaging capability. Furthermore, Cu3BiS3 HNSs could be used for efficient in vivo photothermochemotherapy and X-ray CT imaging of mice bearing melanoma skin cancer. This multifunctional theranostic nanomaterial shows potential promise for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26488908     DOI: 10.1039/c5nr06041a

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  7 in total

Review 1.  A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials.

Authors:  Samireh Badrigilan; Fatemeh Heydarpanahi; Jalal Choupani; Mehdi Jaymand; Hadi Samadian; Mojtaba Hoseini-Ghahfarokhi; Thomas J Webster; Lobat Tayebi
Journal:  Int J Nanomedicine       Date:  2020-09-25

2.  Degradable Hollow Mesoporous Silicon/Carbon Nanoparticles for Photoacoustic Imaging-Guided Highly Effective Chemo-Thermal Tumor Therapy in Vitro and in Vivo.

Authors:  Jinfeng Zhang; Jun Zhang; Wenyue Li; Rui Chen; Zhenyu Zhang; Wenjun Zhang; Yongbing Tang; Xiaoyuan Chen; Gang Liu; Chun-Sing Lee
Journal:  Theranostics       Date:  2017-07-22       Impact factor: 11.556

3.  Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles.

Authors:  Yao Lu; Lihua Li; Zefeng Lin; Mei Li; Xiaoming Hu; Yu Zhang; Mingying Peng; Hong Xia; Gang Han
Journal:  Adv Healthc Mater       Date:  2018-08-13       Impact factor: 9.933

4.  Actively Targeted Deep Tissue Imaging and Photothermal-Chemo Therapy of Breast Cancer by Antibody-Functionalized Drug-Loaded X-Ray-Responsive Bismuth Sulfide@Mesoporous Silica Core-Shell Nanoparticles.

Authors:  Lihua Li; Yao Lu; Chunyan Jiang; Ye Zhu; Xianfeng Yang; Xiaoming Hu; Zefeng Lin; Yu Zhang; Mingying Peng; Hong Xia; Chuanbin Mao
Journal:  Adv Funct Mater       Date:  2017-12-11       Impact factor: 18.808

5.  Photodynamic therapy at ultra-low NIR laser power and X-Ray imaging using Cu3BiS3 nanocrystals.

Authors:  Srivani Veeranarayanan; M Sheikh Mohamed; Aby Cheruvathoor Poulose; Masuko Rinya; Yasushi Sakamoto; Toru Maekawa; D Sakthi Kumar
Journal:  Theranostics       Date:  2018-10-21       Impact factor: 11.556

6.  GO/Bi2S3 Doped PVDF/TPU Nanofiber Membrane with Enhanced Photothermal Performance.

Authors:  Wenxiu Yang; Yonggui Li; Long Feng; Yimiao Hou; Shuo Wang; Bo Yang; Xuemin Hu; Wei Zhang; Seeram Ramakrishna
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

7.  Antimony-Doped Tin Oxide Nanocrystals for Enhanced Photothermal Theragnosis Therapy of Cancers.

Authors:  Zhongjing Lv; Jiafeng Li; Feng Yang; Kun Cao; Qiang Bao; Yuhua Sun; Jian Yuan
Journal:  Front Bioeng Biotechnol       Date:  2020-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.